Search

Your search keyword '"Docanto, M"' showing total 25 results

Search Constraints

Start Over You searched for: Author "Docanto, M" Remove constraint Author: "Docanto, M"
25 results on '"Docanto, M"'

Search Results

1. Independent prognostic impact of plasma NCOA2 alterations in metastatic castration-resistant prostate cancer.

2. Aberrations in circulating ceramide levels are associated with poor clinical outcomes across localised and metastatic prostate cancer

3. Independent prognostic impact of plasma NCOA2 alterations in metastatic castration-resistant prostate cancer

5. Analytical validation of an error-corrected ultra-sensitive ctDNA next-generation sequencing assay.

6. Analytical validation of an error-corrected ultra-sensitive ctDNA next-generation sequencing assay

8. Plasma cell-free DNA concentration andoutcomes in advanced prostate cancer patients treatedwith androgen receptor pathway inhibitors.

9. Whole blood AR-V7 and AR-V9 mRNA expression and treatment response in metastatic castrate-resistant prostate cancer (mCRPC).

10. AR-V7 and AR-V9 expression is not predictive of response to AR-axis targeting agents in metastatic castration-resistant prostate cancer.

11. Plasma cell-free DNA (CFDNA) concentration and outcomes inmetastatic castrate-resistant prostate cancer (MCRPC) patients treatedwith androgen receptor signalling inhibitors (arsis).

12. Whole blood assay for rapid detection of AR-v7 in metastatic castrationresistant prostate cancer: No correlation with response to androgen-axis targeting agents.

13. Detection of AR-V7 transcripts in whole blood RNA of patients with metastatic castration-resistant prostate cancer (MCRPC).

15. Des-acyl ghrelin inhibits oestrogen-stimulated breast tumour growth in vitro and in vivo.

18. BRCA-deficient metastatic prostate cancer has an adverse prognosis and distinct genomic phenotype.

19. Independent prognostic impact of plasma NCOA2 alterations in metastatic castration-resistant prostate cancer.

20. Aberrations in circulating ceramide levels are associated with poor clinical outcomes across localised and metastatic prostate cancer.

21. Analytical validation of an error-corrected ultra-sensitive ctDNA next-generation sequencing assay.

22. Timeless Is a Novel Estrogen Receptor Co-activator Involved in Multiple Signaling Pathways in MCF-7 Cells.

23. Metformin inhibits aromatase expression in human breast adipose stromal cells via stimulation of AMP-activated protein kinase.

24. [Wolman's disease: a case report].

25. [Neonatal hyperthyroidism].

Catalog

Books, media, physical & digital resources